References
- Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. The Lancet [Internet]. 2020;395:470–473. Available from: http://www.sciencedirect.com/science/article/pii/S0140673620301859.
- Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. The Lancet. 2020;395:1014–1015. [place unknown]: Lancet Publishing Group. (vol. 395).
- Petherick A. Developing antibody tests for SARS-CoV-2. The Lancet. 2020;395:1101–1102.
- Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;395:1024–1042.e21. doi:https://doi.org/10.1016/j.cell.2020.09.037.
- Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.e6.
- Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26:1478–1488.
- Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy [Internet]. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/33051445/. [place unknown]: Springer Nature. (vol. 5).
- Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:eabd7728.
- Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi:https://doi.org/10.1126/science.abf4063.
- Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduction and Targeted Therapy. 2020;5:180.
- Wolf J, Kaiser T, Pehnke S, et al. Differences of SARS-CoV-2 serological test performance between hospitalized and outpatient COVID-19 cases. Clin Chim Acta. 2020;511:352–359.
- Liu P, Cai J, Jia R, et al. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. Emerg Microbes Infect. 2020;9:1254–1258.
- Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature [Internet]. 2021:1–10. Available from: https://www.nature.com/articles/s41586-021-03207-w.
- Lei Q, Li Y, Hou H-Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2020;76:all.14622.
- Bošnjak B, Stein SC, Willenzon S, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cellular and Molecular Immunology. 2021;18:936–944. doi:https://doi.org/10.1038/s41423-020-00573-9.
- Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442.
- Meyer B, Reimerink J, Torriani G, et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg Microbes Infect. 2020;9:2394–2403.
- Valcourt EJ, Manguiat K, Robinson A, et al. Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Diagn Microbiol Infect Dis. 2021;99:115294.
- Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369:650–655.
- Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456.
- Gasser R, Cloutier M, Prévost J, et al. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep. 2021;34:108790.
- Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2020;13:eabd2223.
- Mazzini L, Martinuzzi D, Hyseni I, et al. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2021;489:112937.
- Klingler J, Weiss S, Itri V, et al. Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2021;223:957–970. doi:https://doi.org/10.1093/infdis/jiaa784.
- Zhang X-Y, Guo J, Wan X, et al. Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate. Emerg Microbes Infect. 2020;9:2653–2662.
- Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033–1036. doi:https://doi.org/10.1038/s41591-020-0913-5.
- Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12:559. doi:https://doi.org/10.1126/scitranslmed.abc3103.
- Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53:925–933.e4.
- Bolotin S, Tran V, Osman S, et al. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. J Infect Dis. 2021. doi:https://doi.org/10.1093/infdis/jiaa796.